Intimation Details
Aptus Pharma Limited (Scrip Code: 544529, ISIN: INE15XJ01010) submitted a regulatory filing to BSE Limited on August 24, 2026, pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015. The filing contained a press release outlining the company's growth strategy.
Fundraising Plan
The Board of Directors has approved a proposal to raise ₹44.88 crore through a preferential issue of equity shares to identified investors. This proposal is subject to approval by members at the Annual General Meeting scheduled for September 14, 2026, and other applicable statutory and regulatory approvals.
Fund Utilization Plan
Subject to approvals and completion of the preferential issue, the company proposes to utilize the funds as follows:
- ₹25 crore towards capital expenditure (land acquisition, manufacturing plant structure, hi-tech storage facilities, and vehicles)
- ₹10 crore towards working capital requirements
- ₹9.88 crore towards general corporate purposes (operational requirements, corporate exigencies, strategic growth, business expansion, strengthening financial position, enhancement of net worth, and reduction of debt)
The issue proceeds are proposed to be utilized within 36 months from the date of receipt of funds.
Manufacturing Strategy
The company proposes to develop its own manufacturing capabilities with an aspiration to meet approximately 20% of its product requirements through in-house manufacturing. This initiative is expected to strengthen control over product quality, supply-chain management, and product availability while supporting the development of its own-brand portfolio. Implementation is subject to commercial and technical feasibility, availability of funds, and applicable regulatory approvals.
Domestic Expansion
The company intends to progressively strengthen its sales and distribution presence across West, Central, East, and South India as it moves toward broader Pan-India operations.
International Expansion
The company intends to explore opportunities in select international markets including Africa, the Middle East, and Latin America through product registrations, export partnerships, and other permissible business arrangements. Expansion will be pursued progressively subject to commercial viability, market conditions, and applicable regulatory approvals.
Management Commentary
Mr. Tejash Hathi, Managing Director (DIN: 03151221), stated that the strategic direction involves moving from marketing-led operations toward manufacturing capabilities, from regional presence toward Pan-India operations, and from domestic markets toward suitable international opportunities.
Cautionary Statement
The press release contains forward-looking statements, and actual results, outcomes, and implementation timelines may differ depending on commercial feasibility, availability of funds, market conditions, and applicable statutory and regulatory approvals.